Tharimmune (THAR) announced plans for initiating a Phase 2 study evaluating TH104 in patients suffering from moderate-to-severe pruritus associated with primary biliary cholangitis, a rare and chronic liver disease, and also provided a corporate update. The launch of this clinical trial, expected in 2025, follows favorable results from Tharimmune’s Phase 1 study with TH104, recent regulatory feedback from the European Medicines Agency and the U.S. Food and Drug Administration, as well as progress on manufacturing clinical study supply.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THAR:
- Tharimmune initiated with a Buy at Rodman & Renshaw
- Tharimmune presents clinical data on TH104 for chronic pruritus
- Tharimmune granted patent for delivery of molecularly targeted therapeutics
- Tharimmune receives regulatory feedback from EMA for TH104 program
- Tharimmune presents TH104 Phase 1 data at ACG Annual Meeting